Biocircuits' point-of-care (POC) system gets FDA approval:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared Biocircuits' point-of-care immunodiagnostic platform, IOS; the combined T4 and T uptake assay, and a T4-only assay. Biocircuits is developing cartridges for additional physicians' office tests, including one for thyroid stimulating hormone, a serum pregnancy test, and a quantitative hCG test. Approximately 45,000 small to medium sizes practices perform clinical chemistry and haematology testing but do not have immunodiagnostic capabilities. The IOS system will cost around $6,000 and gives results in 20-30 minutes.